Advanced

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?

Prasad, Chandra LU ; Mohapatra, Purusottam LU and Andersson, Tommy LU (2015) In Cancers 7(3). p.1900-1924
Abstract
In recent years, scientists have advocated the use of targeted therapies in the form of drugs that modulate genes and proteins that are directly associated with cancer progression and metastasis. Malignant melanoma is a dreadful cancer type that has been associated with the rapid dissemination of primary tumors to multiple sites, including bone, brain, liver and lungs. The discovery that approximately 40%-50% of malignant melanomas contain a mutation in BRAF at codon 600 gave scientists a new approach to tackle this disease. However, clinical studies on patients have shown that although BRAFi (BRAF inhibitors) trigger early anti-tumor responses, the majority of patients later develop resistance to the therapy. Recent studies have shown... (More)
In recent years, scientists have advocated the use of targeted therapies in the form of drugs that modulate genes and proteins that are directly associated with cancer progression and metastasis. Malignant melanoma is a dreadful cancer type that has been associated with the rapid dissemination of primary tumors to multiple sites, including bone, brain, liver and lungs. The discovery that approximately 40%-50% of malignant melanomas contain a mutation in BRAF at codon 600 gave scientists a new approach to tackle this disease. However, clinical studies on patients have shown that although BRAFi (BRAF inhibitors) trigger early anti-tumor responses, the majority of patients later develop resistance to the therapy. Recent studies have shown that WNT5A plays a key role in enhancing the resistance of melanoma cells to BRAFi. The focus of the current review will be on melanoma development, signaling pathways important to acquired resistance to BRAFi, and why WNT5A inhibitors are attractive candidates to be included in combinatorial therapies for melanoma. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancers
volume
7
issue
3
pages
1900 - 1924
publisher
Multidisciplinary Digital Publishing Institute (MDPI)
external identifiers
  • PMID:26393652
  • Scopus:84941953633
ISSN
2072-6694
DOI
10.3390/cancers7030868
language
English
LU publication?
yes
id
e52c4d5e-1b09-4ff1-96cf-942dce80d03a (old id 8035372)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26393652?dopt=Abstract
date added to LUP
2015-10-03 17:17:48
date last changed
2016-10-13 04:25:21
@misc{e52c4d5e-1b09-4ff1-96cf-942dce80d03a,
  abstract     = {In recent years, scientists have advocated the use of targeted therapies in the form of drugs that modulate genes and proteins that are directly associated with cancer progression and metastasis. Malignant melanoma is a dreadful cancer type that has been associated with the rapid dissemination of primary tumors to multiple sites, including bone, brain, liver and lungs. The discovery that approximately 40%-50% of malignant melanomas contain a mutation in BRAF at codon 600 gave scientists a new approach to tackle this disease. However, clinical studies on patients have shown that although BRAFi (BRAF inhibitors) trigger early anti-tumor responses, the majority of patients later develop resistance to the therapy. Recent studies have shown that WNT5A plays a key role in enhancing the resistance of melanoma cells to BRAFi. The focus of the current review will be on melanoma development, signaling pathways important to acquired resistance to BRAFi, and why WNT5A inhibitors are attractive candidates to be included in combinatorial therapies for melanoma.},
  author       = {Prasad, Chandra and Mohapatra, Purusottam and Andersson, Tommy},
  issn         = {2072-6694},
  language     = {eng},
  number       = {3},
  pages        = {1900--1924},
  publisher    = {ARRAY(0xa510fe8)},
  series       = {Cancers},
  title        = {Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?},
  url          = {http://dx.doi.org/10.3390/cancers7030868},
  volume       = {7},
  year         = {2015},
}